Table 2.
Mouse age | Administration (dose; route; duration) | Mouse strain | Occurrence of first death | TAD rates at the BAPN treatment end point | Effects of AngII on TAD rate | Reference |
Three weeks old | BAPN: 1 g/(kg∙d); in drinking water; four weeks +Ang II: 1000 ng/(kg∙min); by pump; 24–72 h | FVB | NG | 10% AD | Increase | Kurihara et al., 2012 |
NG | 25% TAD | Increase | Ren et al., 2016 | |||
Week 2 | 15% TAR | Increase | Zhao et al., 2019 | |||
C57BL/6 | NG | NG | 73.2% AD/AR | Anzai et al., 2015 | ||
NG | 87% TAD; 20% AR | Remain | Ren et al., 2016 | |||
Week 3 | 80% AD; 20% AR | Remain | Wang et al., 2016 |
AD: aortic dissection; AngII: angiotensin II; AR: aortic rupture; BAPN: β-aminopropionitrile; FVB: Friend leukemia virus B; NG: not given; TAD: thoracic aortic dissection; TAR: thoracic aortic rupture